e-learning
resources
Virtual 2021
06.09.2021
Digital innovations in tuberculosis and implementation research in the era of COVID-19: collaborative activities between the WHO and ERS
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Adherence to treatment for tuberculosis in the digital era
H. Stagg (Edinburgh, United Kingdom)
Source:
Virtual Congress 2021 – Digital innovations in tuberculosis and implementation research in the era of COVID-19: collaborative activities between the WHO and ERS
Session:
Digital innovations in tuberculosis and implementation research in the era of COVID-19: collaborative activities between the WHO and ERS
Session type:
Hot topics
Number:
2602
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Stagg (Edinburgh, United Kingdom). Adherence to treatment for tuberculosis in the digital era. Virtual Congress 2021 – Digital innovations in tuberculosis and implementation research in the era of COVID-19: collaborative activities between the WHO and ERS
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
A new era for treatment of drug-resistant tuberculosis
Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018
Year: 2018
Basics in diagnosis and treatment of tuberculosis
Source: ERS Course 2018 - Summer school of paediatric respiratory medicine
Year: 2018
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
Experience of isofon use for therapy and chemoprophylaxis of tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 486s
Year: 2004
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases
Source: Eur Respir J, 50 (1) 1700648; 10.1183/13993003.00648-2017
Year: 2017
Choice and adherence in preventive treatment for tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 523s
Year: 2003
Current status of fluoroquinolone use for treatment of tuberculosis in Korea
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
The individual-tailored treatment regimens for multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Screening and monitoring of tuberculosis in patients on biologics treatment
Source: Annual Congress 2012 - Tuberculosis: clinical findings I
Year: 2012
Evaluation of treatment outcomes for multidrug-resistant tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 312s
Year: 2001
Re-think first-line tuberculosis treatment
Source: Eur Respir J 2013; 41: 488-489
Year: 2013
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Monitoring during and after tuberculosis treatment
Source: Eur Respir Monogr 2018; 82: 308-325
Year: 2018
Use of molecular-genetic methods in diagnostics and therapy of a tuberculosis (TB) at patients with HIV
Source: Annual Congress 2010 - Tuberculosis in special populations
Year: 2010
Influence of early diagnostics with Xpert MTB/RIF on MDR TB patients treatment efficacy
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015
Management and treatment of multidrug-resistant tuberculosis
Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management
Year: 2019
Surgical treatment of first found pulmonary tuberculosis at ineffectiveness of DOTS therapy
Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions
Year: 2011
Unmasking tuberculosis in the era of antiretroviral treatment
Source: Eur Respir J 2012; 39: 1064-1075
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept